Tool
Interactive Tirzepatide Provider Comparison
This tool projects normalised monthly tirzepatide costs across providers over a period you choose. Only providers whose recurring cost can be computed from public information appear. The basis of each figure is shown, because some include mandatory fees and others are advertised prices whose fee inclusion is unconfirmed.
Key takeaways
- Only providers with a computable recurring cost appear — others are excluded and listed elsewhere.
- The basis of each figure is shown because they are not all measured the same way.
- Projecting over months shows how small monthly differences compound.
- Pharmacy, clinician, and cancellation terms are unverified and are not compared here.
- This tool runs in your browser; nothing you enter is transmitted or stored.
| Providers shown | 5 with a normalisable price |
|---|---|
| Excluded | 19 — see ranking exclusions |
| Comparison basis | Shown per row; not all identical |
| Not compared | Pharmacy, clinicians, states, dose coverage, cancellation |
| Price verified | 2026-07-20 |
Compare providers over time
| Provider | Monthly | Basis | Projected total |
|---|---|---|---|
| TRYM Health | $125 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | — |
| NexLife | $186 | complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee | — |
| Fridays | $240 | advertised monthly rate with medication included and no separate membership fee | — |
| Mochi Health | $278 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | — |
| Eden | $298 | effective recurring cost: medication plus every mandatory fee, computed from the captured components | — |
Why do the bases differ between rows?
Because providers publish pricing differently. Some disclose enough to compute an effective recurring cost including mandatory fees; others advertise a medication price without confirming whether membership or shipping is included. Showing the basis lets you see which comparisons are like-for-like.
The ranking pages apply a stricter filter — see provider rankings for the eligibility rules.
What does this tool deliberately not compare?
Anything unverified: which pharmacy compounds the product, its licence and facility type, named clinicians, states served, dose coverage, shipping terms, and cancellation policy. Those fields are pending verification across the dataset, and comparing them on the basis of marketing claims would produce a confident but unfounded ranking.
Related: Provider rankings · Download the data
What do the verified rates look like?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
What does this page cover, and what does it deliberately leave out?
This page addresses Cost, dose, pharmacy, states, care and terms and evidence, organised around the primary question of compare tirzepatide providers. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Cost | Covered on this page | Regulatory or policy source |
| Dose | Covered on this page | Regulatory or policy source |
| Pharmacy | Covered on this page | Regulatory or policy source |
| States | Covered on this page | Regulatory or policy source |
| Care | Covered on this page | Regulatory or policy source |
| Terms and evidence | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the provider's own quotation |
What are the limits of what this page can tell you?
Every page on this site rests on a specific figures you enter, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the provider's own quotation.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on compare tirzepatide providers.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Which providers are included?
Only those whose recurring tirzepatide cost can be computed from public information.
Why are the bases different?
Providers publish pricing differently; some figures include mandatory fees and others do not confirm them.
Does this compare quality?
No. Pharmacy, clinician, and policy fields are unverified across the dataset and are not compared.
Is my input stored?
No. The tool runs in your browser only.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.